Drug Insight: the use of intravenous immunoglobulin in neurology—therapeutic considerations and practical issues

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Nature Clinical Practice Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/ncpneuro0376PMID 17205073
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial.

  2006cited by this paper
• Follow‐up of four narcolepsy patients treated with intravenous immunoglobulins

  2006cited by this paper
• Narcolepsy and the hypocretin system—where motion meets emotion

  2006cited by this paper
• Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial.

  2005cited by this paper
• Intravenous immunoglobulin and dendritic cells

  2005cited by this paper
• Review: intravenous immunoglobulin therapy and thromboembolic complications

  2005cited by this paper
• Intravenous immunoglobulin

  2005cited by this paper
• Intravenous Immunoglobulins in MS.

  2005cited by this paper
• Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin.

  2005cited by this paper
• Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange.

  2005cited by this paper
• Einsatz von i. v. Immunglobulinen in der Neurologie

  2004cited by this paper
• [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

  2004cited by this paper
• Current Issues in Immunoglobulin Therapies

  2004cited by this paper
• Intravenous immunoglobulins containing antibodies against β-amyloid for the treatment of Alzheimer’s disease

  2004cited by this paper
• Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset

  2004cited by this paper
• Prior poliomyelitis-IVIg treatment reduces proinflammatory cytokine production.

  2004cited by this paper
• Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.

  2004cited by this paper
• Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis

  2004cited by this paper
• How long is IVIg effective in multifocal motor neuropathy?

  2004cited by this paper
• Cost–utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

  2003cited by this paper
• Immunotherapy in autoimmune neuromuscular disorders.

  2003cited by this paper
• Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.

  2003cited by this paper
• Side effects of intravenous immunoglobulins in neurological autoimmune disorders

  2003cited by this paper
• Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies

  2003cited by this paper
• The clinical features of 16 cases of stroke associated with administration of IVIg

  2003cited by this paper
• Arterial thrombosis induced by IVIg and its treatment with tPA

  2003cited by this paper
• Intravenous immunoglobulins neutralize blocking antibodies in Guillain‐Barré syndrome

  2002cited by this paper
• A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy

  2002cited by this paper
• CD4+CD25+ suppressor T cells: more questions than answers

  2002cited by this paper
• Human antibodies against amyloid β peptide: A potential treatment for Alzheimer's disease

  2002cited by this paper
• High-dose intravenous immune globulin for stiff-person syndrome.

  2002cited by this paper
• Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus.

  2002cited by this paper
• Prior poliomyelitis-evidence of cytokine production in the central nervous system.

  2002cited by this paper
• Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

  2001cited by this paper
• Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.

  2001cited by this paper
• Reduced levels of amyloid β-peptide antibody in Alzheimer disease

  2001cited by this paper
• High-dose intravenous immune globulin for stiff-person syndrome.

  2001cited by this paper
• Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy

  2001cited by this paper
• Welding-related parkinsonism: Clinical features, treatment, and pathophysiology

  2001cited by this paper
• Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

  2001cited by this paper
• Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days

  2001cited by this paper
• Multifocal motor neuropathy improved by IVIg

  2000cited by this paper
• High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

  2000cited by this paper
• Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines

  1999cited by this paper
• A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response

  1999cited by this paper
• Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome

  1998cited by this paper
• Clinical trial of plasma exchange and high‐dose intravenous immunoglobulin in myasthenia gravis

  1997cited by this paper
• Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group.

  1997cited by this paper
• Intravenous Immune Globulin Therapy for Neurologic Diseases

  1997cited by this paper
• Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.

  1997cited by this paper
• Treatment of inclusion-body myositis with IVIg

  1997cited by this paper
• Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study.

  1996cited by this paper
• A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy

  1996cited by this paper
• Acute renal failure following immunoglobulin therapy.

  1996cited by this paper
• Reversible encephalopathy with cerebral vasospasm in a Guillain-Barre syndrome patient treated with intravenous immunoglobulin

  1996cited by this paper
• Guillain-Barré syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group.

  1995cited by this paper
• Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study.

  1995cited by this paper
• Intravenous immunoglobulin-induced osmotic nephrosis.

  1994cited by this paper
• A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy

  1994cited by this paper
• A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

  1993cited by this paper
• A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

  1992cited by this paper
• High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

  1981cited by this paper

• Intravenous immunoglobulin use in neurology.

  2026cites this paper
• Prospects for multi-focal motor neuropathy treatment by complement inhibition

  2025cites this paper
• Guillain-Barré-Syndrom (GBS)

  2025cites this paper
• Potential Alteration Enabled Peptide Elongation for Direct Serum Detection of S100B in the Early Screening of Phenylketonuria

  2023cites this paper
• Vaccination and immunotherapies in neuroimmunological diseases

  2022cites this paper
• Intravenous immunoglobulin in COVID-19 associated Guillain–Barré syndrome in pregnancy

  2021cites this paper
• Update on Intravenous Immunoglobulin in Neurology: Modulating Neuro-autoimmunity, Evolving Factors on Efficacy and Dosing and Challenges on Stopping Chronic IVIg Therapy

  2021cites this paper
• Advances in immunotherapy for the treatment of spinal cord injury.

  2020cites this paper
• Tratamiento de la esclerosis múltiple

  2019cites this paper
• Konsensuspapier zum Einsatz der therapeutischen Apherese in der Neurologie

  2019cites this paper
• Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review

  2019cites this paper
• Use of Intravenous Immunoglobulin in Neurology

  2018cites this paper
• Aβ levels in the jugular vein and high molecular weight Aβ oligomer levels in CSF can be used as biomarkers to indicate the anti-amyloid effect of IVIg for Alzheimer’s disease

  2017cites this paper
• Immune Modulatory Therapy Causing Acute Coronary Syndrome

  2017cites this paper
• Immunoglobulin therapy in the treatment of multifocal motor neuropathy.

  2017cites this paper
• Endothelial Cell Amplification of Regulatory T Cells Is Differentially Modified by Immunosuppressors and Intravenous Immunoglobulin

  2017cites this paper
• Clinical experiences in primary and secondary immunodeficiencies and immune-mediated conditions using Gammanorm(®).

  2016cites this paper
• 10% liquid human immunoglobulin (KIOVIG(®)) for immunomodulation in autoimmune disorders.

  2016cites this paper
• B-Cell Depletion with CD20 Antibodies as New Approach in the Treatment of Inflammatory and Immunological Events Associated with Spinal Cord Injury

  2016cites this paper
• INTERNATIONAL CONSENSUS GUIDANCE FOR THE MANAGEMENT OF MYASTHENIA GRAVIS

  2016cites this paper
• Medication use while breastfeeding with multiple sclerosis: A systematic literature review

  2016cites this paper
• Intravenous immunoglobulins for the treatment of mild to moderate Alzheimer ’ s disease : a phase II , randomised , double-blind , placebo-controlled dose-finding trial

  2016cites this paper
• Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation

  2016cites this paper
• Efficacy of Polyvalent Human Immunoglobulins in an Animal Model of Neuromyelitis Optica Evoked by Intrathecal Anti-Aquaporin 4 Antibodies

  2016cites this paper
• Antigen Receptor-Intrinsic Non-Self: The Key to Understanding Regulatory Lymphocyte-Mediated Idiotypic Control of Adaptive Immune Responses.

  2016cites this paper
• Immunmodulatorische Therapie und Plasmaaustausch

  2015cites this paper
• Autoantibodies in CNS Trauma and Neuropsychiatric Disorders

  2015cites this paper
• Induction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate Immunity

  2015cites this paper
• Infektiologische Risiken in der Multiple-Sklerose-Therapie durch infundierbare Immuntherapeutika

  2015cites this paper
• Prophylactic treatment with sulphonated immunoglobulin G attenuates development of mechanical allodynia-like response in mice with neuropathic pain

  2015cites this paper
• Long‐Term Response of Neuropathic Pain to Intravenous Immunoglobulin in Relapsing Diabetic Lumbosacral Radiculoplexus Neuropathy. A Case Report

  2014cites this paper
• The paradox of chronic neuroinflammation, systemic immune suppression, autoimmunity after traumatic chronic spinal cord injury.

  2014cites this paper
• Multiple sclerosis treatment and infectious issues: update 2013

  2014cites this paper
• Clinical applications of immunoglobulin in neuromuscular diseases: focus on inflammatory myopathies.

  2014cites this paper
• The paradox of chronic neuroinflammation , systemic immune suppression and autoimmunity after traumatic chronic spinal cord injury

  2014cites this paper
• High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis

  2014cites this paper
• Enhanced Anti-Diabetogenic Effect of Intravenous Immune Globulin Modified by Ferrous Ion Exposure

  2014cites this paper
• Neurologic disease due to HTLV-1 infection.

  2014cites this paper
• The anti-inflammatory properties of intravenous immunoglobulin in a murine model of allergic airway disease ; effects on the development of regulatory T-cells

  2013cites this paper
• Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial.

  2013cites this paper
• Intravenous Gammaglobulin Inhibits Encephalitogenic Potential of Pathogenic T Cells and Interferes with their Trafficking to the Central Nervous System, Implicating Sphingosine-1 Phosphate Receptor 1–Mammalian Target of Rapamycin Axis

  2013cites this paper
• Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives

  2013cites this paper
• PARAPARESIA ESPÁSTICA TROPICAL / MIELOPATÍA ASOCIADA A HTLV (PET/MAH). REPORTE DE CASOS EN EL PACÍFICO COLOMBIANO TROPICAL SPASTIC PAPARESIS / HTLV-ASSOCIATED MYELOPATHY (TSP/HAM). CASE REPORTS IN COLOMBIAN PACIFIC COAST

  2013cites this paper
• Mammalian Target of Rapamycin Axis - phingosine-1 Phosphate Receptor 1 the Central Nervous System, Implicating S Cells and Interferes with their Trafficking to Encephalitogenic Potential of Pathogenic T Intravenous Gammaglobulin Inhibits

  2013cites this paper
• Clinical course of acute canine polyradiculoneuritis following treatment with human IV immunoglobulin.

  2012cites this paper
• Immunomodulation in Adult Epilepsy: The Role of IVIG

  2012cites this paper
• 68 Diagnostik und Therapie der Myasthenia gravis und des Lambert-Eaton-Syndroms

  2012cites this paper
• Peripheral nerve diseases

  2012cites this paper
• Naturally occurring antibodies as therapeutics for neurologic disease: can human monoclonal IgMs replace the limited resource IVIG?

  2012cites this paper
• Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system.

  2012cites this paper
• Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle.

  2012cites this paper
• Sub-acute demyelinating polyradiculoneuropathy as an initial symptom of peripheral T cell lymphoma, not otherwise specified (PTCL-NOS).

  2012cites this paper
• B cells and antibodies in multiple sclerosis pathogenesis and therapy

  2012cites this paper
• Intervenous immunoglobulins as modulators of immune response : effect on T cell polarisation, pathogenicity and trafficking

  2012cites this paper
• Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.

  2012cites this paper
• Treatment of Neurological Autoimmune Diseases with Immunoglobulins: First Insights from the Prospective SIGNS Registry

  2012cites this paper
• Immunoglobulins for primary or secondary immunodeficiency or for immunomodulation in neurological autoimmune diseases: insights from the prospective SIGNS registry

  2012cites this paper
• Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy

  2012cites this paper
• Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis

  2011cites this paper
• A Differential Concentration-Dependent Effect of IVIg on Neutrophil Functions: Relevance for Anti-Microbial and Anti-Inflammatory Mechanisms

  2011cites this paper
• Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy

  2011cites this paper
• Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

  2011cites this paper
• Inhibition of differentiation, amplification, and function of human TH17 cells by intravenous immunoglobulin.

  2011cites this paper
• Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study

  2011cites this paper
• Emerging drugs for Guillain-Barré syndrome

  2011cites this paper
• RIIIA-Dependent Mechanisms g Airway Inflammation through Fc Invariant NKT Cell-Mediated Allergic Cutting Edge: Intravenous Ig Inhibits

  2011cites this paper
• Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.

  2011influential citation
• The effect of IgG levels on the number of natural killer cells and their Fc receptors in chronic inflammatory demyelinating polyradiculoneuropathy

  2011cites this paper
• Cutting Edge: Intravenous Ig Inhibits Invariant NKT Cell-Mediated Allergic Airway Inflammation through FcγRIIIA-Dependent Mechanisms

  2011cites this paper
• Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies.

  2011cites this paper
• L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous use.

  2011cites this paper
• Standard and escalating treatment of chronic inflammatory demyelinating polyradiculoneuropathy

  2011cites this paper
• Molecular and clinical effects of betamethasone in human t‐cell lymphotropic virus type‐i‐associated myelopathy/tropical spastic paraparesis patients

  2011cites this paper
• Potential biomarkers for monitoring therapeutic response in patients with CIDP

  2011cites this paper
• Intravenous Immunoglobulin in the Treatment of Neurological Diseases

  2011cites this paper
• Multifocal motor neuropathy in the Netherlands : immunology, genetics and treatment

  2011cites this paper
• Multiple Sklerose und Infektionskrankheiten

  2011cites this paper
• Can we face the challenge of expanding use of intravenous immunoglobulin in neurology?

  2010cites this paper
• sHLA-I Contamination, A Novel Mechanism to Explain Ex Vivo/In Vitro Modulation of IL-10 Synthesis and Release in CD8+ T Lymphocytes and in Neutrophils Following Intravenous Immunoglobulin Infusion

  2010cites this paper
• Good maternal and fetal outcomes of predominantly sensory Guillain–Barré syndrome in pregnancy after intravenous immunoglobulin

  2010cites this paper
• Klinische Studien und Therapieoptionen bei Immunneuropathien

  2010cites this paper
• Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy

  2010influential citation
• Immunomodulatory Therapies in Neurologic Critical Care

  2010cites this paper
• Intravenous immunoglobulin therapy for patients with idiopathic cardiomyopathy and endomyocardial biopsy-proven high PVB19 viral load

  2010cites this paper
• IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN.

  2010cites this paper
• Intravenous Immunoglobulins Promote Skin Allograft Acceptance by Triggering Functional Activation of CD4+Foxp3+ T cells

  2010cites this paper
• Intravenous Immunoglobulins as a Treatment for Alzheimer’s Disease

  2010cites this paper
• Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion

  2010cites this paper
• Kinderwunsch und Multiple Sklerose

  2010cites this paper
• Identification and comparison of adverse events for preparations of IVIG in patients with neuromuscular diseases.

  2010cites this paper
• Comparative analysis of therapeutic options used for myasthenia gravis

  2010influential citation
• Immunomodulation by Intravenous Immunoglobulin: Role of Regulatory T Cells

  2010cites this paper
• Chapter 14 - Attack Therapies in Multiple Sclerosis

  2010cites this paper
• [Intravenous immunoglobulins in multiple sclerosis. An update].

  2009cites this paper
• Intravenous Immunoglobulins after Liver Transplantation: new insights in mechanisms of action

  2009cites this paper
• Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

  2009cites this paper
• Bedeutung intravenöser Immunglobuline zur Behandlung immunvermittelter Polyneuropathien

  2009cites this paper
• Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin

  2009cites this paper
• Intravenous immunoglobulin as rescue therapy for BK virus nephropathy

  2009cites this paper
• Intravenöse Immunglobuline bei Multipler Sklerose

  2009cites this paper